Literature DB >> 25527981

Development of a purity control strategy for pemetrexed disodium and validation of associated analytical methodology.

Anne Warner1, Irina Piraner2, Heather Weimer2, Kevin White2.   

Abstract

Stability-indicating reversed phase HPLC methods have been developed and validated for the determination of 13 potential process and degradation impurities in pemetrexed disodium drug substance (DS) and pemetrexed for injection drug product (DP). This paper describes the development of HPLC-UV impurity methods for drug substance and drug product. Relative response factors (RRF) have been determined using HPLC-UV in tandem with CAD or by NMR detection. Conditions for the generation of system suitability solutions are described and assure adequate chromatographic resolution and peak identification without the need for impurity reference standards. The methods were fully validated and demonstrated to have acceptable specificity, linearity, accuracy, repeatability, intermediate precision, detection/quantitation limit, and robustness.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Impurity control; Method validation; Pemetrexed disodium; Relative response factor determination; System suitability

Mesh:

Substances:

Year:  2014        PMID: 25527981     DOI: 10.1016/j.jpba.2014.11.032

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  2 in total

1.  Effect of Formulation Factors and Oxygen Levels on the Stability of Aqueous Injectable Solution Containing Pemetrexed.

Authors:  Dong Han Won; Heejun Park; Eun-Sol Ha; Yong Min Kim; Hyung Don Hwang; Sun Woo Jang; Min-Soo Kim
Journal:  Pharmaceutics       Date:  2020-01-06       Impact factor: 6.321

2.  Liquid crystalline assembly for potential combinatorial chemo-herbal drug delivery to lung cancer cells.

Authors:  Hadeer M Abdelaziz; Ahmed O Elzoghby; Maged W Helmy; Magda W Samaha; Jia-You Fang; May S Freag
Journal:  Int J Nanomedicine       Date:  2019-01-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.